Polypragmasia in ophthalmic practice
- Authors: Moshetova L.1, Soshina M.2, Sychev D.2, Turkina K.2, Lopareva A.1
-
Affiliations:
- I.M. Sechenov First Moscow State Medical University (Sechenov University)
- Russian Medical Academy of Continuing Professional Education
- Issue: Vol 29, No 7 (2018)
- Pages: 40-43
- Section: Articles
- URL: https://journals.eco-vector.com/0236-3054/article/view/117184
- DOI: https://doi.org/10.29296/25877305-2018-07-08
- ID: 117184
Cite item
Open Access
Access granted
Abstract
The paper provides a discussion of the clinical case of female patient P. aged 70 years, who applied for examination to the Advisory Department, Eye Hospital, with the previously verified diagnosis of grade 1a open-angle glaucoma, early cataract, and mild hypermetropia. During instillations of the local formulation of a ß-adrenoblocker and an а-adrenomimetic in combination with paroxetine (an antidepressant of the selective serotonin reuptake inhibitor group), the patient developed weakness, hypotension, and bradycardia (blood pressure, 100/60 mm Hg; heart rate, 58 beats/min). In this case, there was a serious adverse reaction that was significantly associated with the adverse drug interaction according to the Horn-Hansten scale).
Keywords
Full Text
About the authors
L. Moshetova
I.M. Sechenov First Moscow State Medical University (Sechenov University)Professor, MD, Academician of the Russian Academy of Sciences
M. Soshina
Russian Medical Academy of Continuing Professional Education
D. Sychev
Russian Medical Academy of Continuing Professional EducationProfessor, MD, Corresponding Member of the Russian Academy of Sciences
K. Turkina
Russian Medical Academy of Continuing Professional EducationCandidate of Medical Sciences
A. Lopareva
I.M. Sechenov First Moscow State Medical University (Sechenov University)
References
- Walckies D., Van der Heyden J., Tafforeau J. Factors associated with excessive polypharmacy in older people // Arch. Public Health. - 2015; 73: 50.
- Полипрагмазия в клинической практике: проблема и решения. Под ред. Д.А. Сычева / СПб: ЦОП «Профессия», 2016; с. 9.
- Офтальмология: национальное руководство. Под ред. С.Э. Аветисова, Е.А. Егорова, Л.К. Мошетовой, В.В. Нероева, Х.П. Тахчиди / М.: ГЭОТАР-Медиа, 2013; с. 767-9.
- Ильина Е.С., Богова О.Т., Горбатенкова С.В. и др. Падение пациента старческого возраста как неблагоприятное событие, связанное с применением лекарственных средств: клиническое наблюдение // Рац. фармакотер. в кардиол. - 2017; 13 (2): 203-6.
- Korte J.-M., Kaila T., Saari M. Systemic bioavailability and cardiopulmonary effects of 0.5% timololeyedrops // Graefe's Arch. Clin. Exp. Ophthalmol. - 2002; 240: 430-5.
- Абдрашитов Р.Х., Гильдеева Г.Н., Раменская Г.В. и др. Обзор существующих методик оценки активности CYP2D6 с применением экзогенных и эндогенных маркеров // Фармакокинетика и фармакодинамика. - 2015; 1: 4-11.
- Volotinen M., Turpeinen M., Tolonen A. et al. Timolol metabolism in human liver microsomes is mediated principally by CYP2D6 // Drug Metabol. Disposition. - 2007; 35: 1135-41.
- Чаукина С.В. Клинико-фармакологические аспекты метаболизма лекарственных средств под действием изофермента цитохрома Р-450 CYP2D6 // Трудный пациент. - 2008; 14 (5): 31-3.
- Volotinen M., Korjamo T., Tolonen A. et al. Effects of selective serotonin reuptake inhibitors on timolol metabolism in human liver microsomes and cryopreserved hepatocytes // Basic Clin. Pharmacol.Toxicol. - 2010; 106: 302-9.
- Bertelsen K., Venkatakrishnan K., Von Moltke L. et al. Apparent mechanism-based inhibition of human CYP2D6 in vitro by paroxetine: comparison with fluoxetine and quinidine // Drug Metabol. Disposition. - 2003; 31: 289-93.
- Mäenpää J., Volotinen-Maja M., Kautiainen H. et al. Paroxetine markedly increases plasma concentrations of ophthalmic timolol; CYP2D6 inhibitors may increase the risk of cardiovascular adverse effects of 0.5% timolol eye drops // Drug Metabol. Disposition. - 2014; 42: 2068-76.
- Mäenpää J., Pelkonen O. Cardiac safety of ophthalmic timolol // Expert Opin. Drug Safety. - 2016; 15: 1549-61.
- Huber M., Kölzsch M., Stahlmann R. Ophthalmic drugs as part of polypharmacy in nursing home residents with glaucoma // Drugs Aging. - 2013; 30: 31-8.
- Horn J., Hansten P., Chan L. Proposal for a new tool to evaluate drug interaction cases // Ann. Pharmacother. - 2007; 41 (4): 674-80.
- Казаков А.С. Определение степени достоверности причинноследственной связи «Нежелательная реакция - взаимодействие лекарственных средств» // Рус. мед. журн. - 2013; 5: 38-43.
- Сычев Д.А., Отделенов В.А., Краснова Н.М. и др. Полипрагмазия: взгляд клинического фармаколога // Тер. арх. - 2016; 12: 94-102.
Supplementary files
